Treatment of diabetic retinopathy with whole human post-translationally modified anti-VEGF Fab

Described are methods for using a fully human post-translationally modified (HuPTM) monoclonal antibody ("mAb") or antigen binding fragment of mAb against human vascular endothelial growth factor ("hVEGF"), such as, for example, an antigen binding fragment of mAb. The present invention relates to compositions and methods for delivery of a fully human glycosylated (HuGly) anti-hVEGF antigen binding fragment to the retinal/vitreous humor in the eye of a human subject diagnosed with diabetic retinopathy. The invention relates to compositions and methods for the delivery of a fully human glycosylated (HuGly) anti-hVEGF antigen binding fragment to the retinal/vitreous humor in the eye of a human subject diagnosed with diabetic retinopathy. 描述了用于将针对人血管内皮生长因子("hVEGF")的全人经翻译后修饰的(HuPTM)单克隆抗体("mAb")或mAb的抗原结合片段--例如，全人经糖基化的(HuGly)抗hVEGF抗原结合片段--递送到被诊断患有糖尿病性视网膜病变的人类受试者的眼睛中的视网膜/玻璃体液(vitreal humour)的组合物和方法。